Back to Search Start Over

Variation in the Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features.

Authors :
Chen DW
Rob FI
Mukherjee R
Giordano TJ
Haymart MR
Banerjee M
Source :
The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2022 Sep 28; Vol. 107 (10), pp. e4072-e4077.
Publication Year :
2022

Abstract

Context: Noninvasive encapsulated follicular variant of papillary thyroid cancer was reclassified as noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) in January 2017. The impact of this nomenclature change at a population level remains unknown.<br />Objective: Examine use of NIFTP across different US regions and populations.<br />Design: Descriptive epidemiology study using SEER-22 data (2000-2019).<br />Participants: Individuals diagnosed with papillary or follicular thyroid cancer (2000-2019) or NIFTP (2017-2019).<br />Main Outcome Measures: Annual incidence rates of thyroid cancer by subtype and NIFTP. Using 2018-2019 data, (1) rates of NIFTP at the 17 SEER-22 sites and (2) comparison of demographics for patients diagnosed with NIFTP vs papillary and follicular thyroid cancer.<br />Results: NIFTP comprised 2.2% and 2.6% of cases in 2018 and 2019, respectively. Between 2018 and 2019, large heterogeneity was observed in the regional use of NIFTP diagnosis, with site-specific incidence rates between 0.0% and 6.2% (median 2.8%, interquartile range 1.3-3.6%). A diagnosis of NIFTP (vs papillary and follicular thyroid cancer) in 2018 and 2019 was significantly associated with older age (P = 0.012 and P = 0.009, respectively), Black race (both Ps < 0.001), and non-Hispanic ethnicity (both Ps < 0.001).<br />Conclusions: Marked variation exists in the use of the NIFTP diagnosis. The recent 2021 coding change that resulted in NIFTP, a tumor with uncertain malignant potential and for which there is no long-term outcome data available, no longer being a reportable diagnosis to SEER will disproportionately affect vulnerable patient groups such as older patients and Black patients, in addition to patients who reside in regions with higher rates of NIFTP diagnoses.<br /> (© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)

Details

Language :
English
ISSN :
1945-7197
Volume :
107
Issue :
10
Database :
MEDLINE
Journal :
The Journal of clinical endocrinology and metabolism
Publication Type :
Academic Journal
Accession number :
35918064
Full Text :
https://doi.org/10.1210/clinem/dgac466